Statistical considerations about the question of a selection of discriminating centres in the analysis of clinical trial. In response to the paper: "A method for controlling for a high response rate in a comparison of venlafaxine XR and diazepan in the short-term treatment of patients with generalised anxiety disorder".
Falissard
Bruno
B
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D015982:Bias; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D003625:Data Collection / Q000706:statistics & numerical data; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D018757:GABA Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D014151:Anti-Anxiety Agents; D003511:Cyclohexanols; D003975:Diazepam; D018757:GABA Modulators; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride